Research programme: leucocyte elastase inhibitors - NAEJA
Alternative Names: Leucocyte elastase inhibitors research programme - NAEJA; Neutrophil elastase inhibitors research programme - NAEJA; Research programme: neutrophil elastase inhibitors - NAEJA; SYN 1390; SYN 1396Latest Information Update: 03 Dec 2004
At a glance
- Originator NAEJA Pharmaceutical
- Class
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis; Emphysema
Most Recent Events
- 18 Nov 2004 Discontinued - Preclinical for Cystic fibrosis in Canada (Inhalation)
- 18 Nov 2004 Discontinued - Preclinical for Emphysema in Canada (Inhalation)
- 03 Apr 2003 NAEJA Pharmaceutical's leucocyte elastase inhibitors programme is available for licensing in the indication of cystic fibrosis (http://www.naeja.com)